Lorlatinib Continuation Study (clinicaltrials.gov) - Sep 24, 2026 - P4 | N=76 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Dec 2026 ➔ Oct 2029 | Trial primary completion date: Dec 2026 ➔ Oct 2029
Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|